Drug Profile
Rotigotine controlled release - Serina Therapeutics
Alternative Names: SER-214Latest Information Update: 09 May 2023
Price :
$50
*
At a glance
- Originator Serina Therapeutics
- Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 09 May 2023 Serina Therapeutics plans phase-II trial for Parkinson's disease (Serina Therapeutics pipeline; April 2023)
- 21 Apr 2023 Rotigotine controlled release is still in phase-I trials for Parkinson's disease (Early-stage disease) in USA (SC, Injection) (Serina Therapeutics pipeline; April 2023)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Parkinson's-disease(Early-stage disease) in USA (SC, Injection)